Advanced Therapy Solutions
Kelly Kester, Director of Product Management, Advanced Therapy Solutions
The development of cell and gene therapies (CGT) has grown exponentially in the past decade. Despite only approximately 10 FDA-approved therapies, over 3,000 are currently in development worldwide. CGTs introduce unprecedented challenges from the development, manufacturing, and logistics of these products, among others. From delivering cryogenic materials, to specialized workforce training and coordinating patient travel to treatment centers, new development heavily relies on partners who understand—and can handle the complexities.
With more than a decade of experience consulting and collaborating with biopharma companies on CGT products, Cardinal Health is well-versed in the challenges facing these companies. In 2022, they launched the Advanced Therapy Solutions division to support biopharma companies with a high-touch, coordinated customer experience while navigating the complexities of the industry.
With experience handling regulatory consulting for 40+ advanced therapies, providing regulatory support for 12 therapeutic areas, processing more than 8k cell therapy orders, and supporting the launch of the first CAR-T products, Cardinal Health’s team has expansive knowledge in the space. Although the division is under a year old, it is developing integrated solutions to remove obstacles and delays for innovative therapies with real-world evidence and outcomes, regulatory consulting, site-of-care logistics, order-to-cash management, and patient access and support.
Within the first year of launch, Cardinal Health is already seeing the value. In one instance, the team developed a novel approach for cash management/third-party logistics on-site. In another instance, a travel and lodging program was developed to assist patients receiving treatment. And, as new products come to market the team is passionate about creating standardization within the industry without compromising tailored solutions.